Immunotherapy developer Adicet Bio revealed the series A funding alongside its acquisition of Israel-based Applied Immune Technologies.

US-based biopharmaceutical company Adicet Bio closed a $51m series A round yesterday featuring Novartis Venture Fund, the corporate venturing arm of pharmaceutical firm Novartis. The round was led by healthcare-focused investment firm OrbiMed and included venture capital firm Pontifax. Adicet concurrently announced it has acquired Israel-based immunotherapies developer Applied Immune Technologies (AIT) for an undisclosed…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.